General discussion, page-14985

I had the same concern about APIRx initially, when there was a vacuum of information about their intentions towards the new drug candidates.
But that vacuum was filled, and I can't find fault with how management has proceeded with prioritisation and funding from the previous options raise.

Even if only one APIRx drug candidate eventuates, it will have been worth the acquisition AND the latest CR, if we want to argue that acquiring APIRx was a significant factor in needing the raise. With 22 candidates, some of them significantly de-risked already, and all benefitting from the inherent de-risking we all recognise in the long history of humanity's cannabinoid use and cannabinoid integration with human neurology, I'm comfortable calling the odds heavily in favour of the acquisition being an excellent move, long term. But as you say: time will tell.